This episode’s guest, Melinda Mayorga, RN, MSN, CNS, AGCNS-BC, OCN, a clinical nurse specialist at Norris Comprehensive ...

Oncology nurses and APPs are key players in patient education on precision medicine.

The FDA has granted accelerated approval to subcutaneous treatment with mosunetuzumab (Lunsumio VELO™), a CD20xCD3 bispecific antibody, for adult patients with relapsed or refractory follicular ...

Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...

CAR T-cell therapy has revolutionized the treatment of certain hematologic malignancies, providing durable remissions for ...

The FDA has approved the use of subcutaneous amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for use in all approved ...

The FDA has granted standard approval to rucaparib (Rubraca) for the treatment of patients with metastatic ...

Young, Empowered, and Strong (YES), a mobile health intervention, was linked to improved general and cancer-specific ...

Hormone replacement therapy (HRT) does not have an adverse effect on breast cancer risk, according to findings from an ...

The FDA has greenlit niraparib and abiraterone acetate (AAP; Akeega) with prednisone for the treatment of adults with deleterious or suspected deleterious BRCA2 -mutated metastatic hormone-sensitive ...

The use of sacituzumab govitecan to treat HR+/HER2– metastatic breast cancer did not reach its primary end point of ...

Onc Nurse On Call is the new podcast by Oncology Nursing News, hosted by editors-in-chief Patricia Jakel, MN, RN, AOCN, and ...